Peter Cicala
Directeur/Membre du Conseil chez ETERNA THERAPEUTICS INC.
Profil
Peter Cicala is the founder of Boundless Bio, Inc. (founded in 2019).
He is currently working as an Independent Director at Eterna Therapeutics, Inc. since 2024.
Previously, he held the position of Chief Intellectual Property Counsel at Intercept Pharmaceuticals, Inc. from 2020 to 2021 and Chief Patent Counsel at Celgene Corp.
from 2014 to 2019.
Mr. Cicala completed his undergraduate degree at Fairleigh Dickinson University and his graduate degree at Seton Hall University School of Law.
Postes actifs de Peter Cicala
| Sociétés | Poste | Début |
|---|---|---|
| ETERNA THERAPEUTICS INC. | Directeur/Membre du Conseil | 12/02/2024 |
Anciens postes connus de Peter Cicala
| Sociétés | Poste | Fin |
|---|---|---|
| INTERCEPT PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/03/2021 |
| CELGENE | Corporate Officer/Principal | 01/11/2019 |
| BOUNDLESS BIO, INC. | Fondateur | - |
Formation de Peter Cicala
| Seton Hall University School of Law | Graduate Degree |
| Fairleigh Dickinson University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| ETERNA THERAPEUTICS INC. | Health Technology |
| BOUNDLESS BIO, INC. | Health Technology |
| INTERCEPT PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |